Press Releases and News
A major theme at MiBio 2019 focused on strategies to address challenges in protein-protein interactions, formulation, drug product development and competitive product profiles. Conversations quickly honed in around the increasing reliance on microfluidic modulation spectroscopy to obtain insights into structural changes in proteins during biopharmaceutical product development. The technology is quickly becoming the go-to solution in … “MIBio: A Huge Success for RedShiftBio”
We recently exhibited at the 9th annual American Drug Delivery & Formulation Summit, in Boston MA. The Summit focused on challenges of developing biopharmaceutical formulations, and the latest trends and technologies to improve drug delivery. The key message was encouraging a drug delivery mind-set from discovery through to production. Researchers learned about formulation design, optimizing formulation … “Monitoring protein aggregation in biotherapeutics – a hot topic at the 9th annual American Drug Delivery & Formulation Summit”
We have just returned from Bioprocessing Summit 2019 in our hometown of Boston. Over 1400 industry professionals attended a mixture of talks, posters and networking. Our booth was a popular destination, with many visitors stopping by to learn more about the AQS3TMpro. A hot topic at the conference was monitoring protein aggregation, the process by … “Protein Aggregation Monitoring was Hot Topic at Bioprocessing Summit”
The 25th Anniversary Colorado Protein Stability Conference focused on protein stability and aggregation from a range of perspectives including computational modeling risk management, and formulation development. Researchers from numerous disciplines, ranging from biochemical research and clinical biochemistry to pharmaceutical development and manufacturing. The poster sessions were particularly lively, with many people stopping by to see … “Researchers From Numerous Disciplines Gather At The Colorado Protein Stability Conference”
RedShift Bioanalytics’ instrumentation was crucial in ground-breaking developments in the detection and treatment of Alzheimer’s Disease (AD). The AQS3 TMpro, based on the company’s proprietary Microfluidic Modulation Spectroscopy, provided scientists from the University of Washington insight into the formation of small amyloid beta aggregates, the elements now believed to cause cognitive impairment typical in AD.
One year on from introducing the AQS3TMpro, a powerful new protein characterization solution, we demonstrated compelling new application data and significant endorsements from leading biopharmaceutical companies at PEGS 2019. Driven by industry-leading AQS3delta analytical software, the AQS3pro is transforming the utility of IR spectroscopy for the analysis of protein structure, delivering high sensitivity results in … “Inspiring innovative biotherapeutic protein drug development at PEGS 2019”
HOS 2019 highlighted the range of biophysical characterization methods and tools used in monitoring the attributes of protein therapeutics such as conformation and higher order structure. We showcased AQSpro with Microfluidic Modulation Spectroscopy (MMS), a system that addresses the limitations of current products such as FTIR, and provides an efficient tool for direct, label-free protein … “Scientists See Change in Higher Order Structure with MMS, at HOS 2019”
One year on from introducing the AQS3pro, a powerful new protein characterization platform, RedShift™ BioAnalytics, Inc. (RedShiftBio) is demonstrating compelling new application data and significant endorsements from leading biopharmaceutical companies.
We have just returned from the Biotherapeutics Analytical Summit in Virginia. What a great celebration of the conference’s 10th birthday! We were inundated with fascinating conversations, the most popular being the characterization of higher order structure (or HOS). We presented a poster with Elion Labs on the study of HOS of IgG Samples Spiked with … “Higher Order Structure: The Hot Topic of Biotherapeutics Analytical Summit”
Critical Quality Attributes to Advance Therapeutics and Vaccines from Candidate Selection to Drug Product Biotherapeutics and vaccines are critical in improving public health. They are being developed for acute and chronic clinical indications that cover the spectrum from infectious diseases to oncology. The development of biologics, from candidate engineering and selection, through expression, purification, formulation, … “RedShiftBio Joined Thought Leaders at Biotherapeutics and Vaccines Development (Gordon Research Conference)”